centerforbiosimilars3 小时
Real-World UK, Ireland Study Confirms Long-Term Efficacy of SB5 in Psoriasis
SB5, an adalimumab biosimilar approved in the US, is showing to be safe and effective for patients with psoriasis in the long term, according to a study from the UK and Ireland.
centerforbiosimilars6 小时
FDA Reviews Golimumab Biosimilar, Samsung Biologics Hits Record Sales, Japan Approves ...
The FDA accepted applications for a golimumab biosimilar, while Samsung Biologics reported record sales, and a Japanese ...
centerforbiosimilars19 小时
Prateek Yadav, MPTh, MBA
The Top 5 Biosimilar Articles for the Week of December 2 ...
centerforbiosimilars1 天
Gary Fanjiang, MD, MBA, MS
The Top 5 Biosimilar Articles for the Week of December 2 ...
centerforbiosimilars1 天
Courtney Flaherty
The Top 5 Biosimilar Articles for the Week of December 2 ...
centerforbiosimilars1 天
Amanda Forys, MSPH
The Top 5 Biosimilar Articles for the Week of December 2 ...
centerforbiosimilars2 天
Long-Term Data Support Use of Eculizumab Biosimilar as Soliris Alternative in PNH
Eculizumab biosimilar Elizaria demonstrates long-term safety and efficacy comparable with the reference product Soliris in ...
centerforbiosimilars2 天
Robert Rifkin, MD, FACP
The Top 5 Biosimilar Articles for the Week of December 2 ...
centerforbiosimilars2 天
Christina Corridon, MPH, MBA
The Top 5 Biosimilar Articles for the Week of December 2 ...
centerforbiosimilars2 天
Mike Gladstone
Strengthening the Supply Chain: Key Insights From FDA Commissioner Dr Robert Califf ...
centerforbiosimilars3 天
Switching From Ustekinumab to Biosimilar SB17 Maintains Efficacy, Safety in Patients With ...
Biosimilar SB17 demonstrated clinical biosimilarity to reference ustekinumab after switching and maintained long-term ...